《他汀不耐受的临床诊断与处理中国专家共识》解读:一部有助于管好中国人群血脂的“导航仪”

Interpretation of Chinese Expert Consensus on the Diagnosis and Management Strategy of Patients with Statin Intolerance: A guiding file for lipid management in Chinese population

业已证实,低密度脂蛋白胆固醇(LDL-C)水平升高是动脉粥样硬化性心血管疾病(ASCVD)发生的致病性危险因素,他汀类药物的临床应用开启了ASCVD病因学治疗的新时代。同时,他汀类药物也是国内外众多指南一致推荐的血脂管理及防治ASCVD的基石性药物。然而,他汀类药物不耐受现象(简称他汀不耐受)临床上并非少见,真实世界临床实践中的诊断与处理也存在困惑与误区。据此,国家心血管病专家委员会心血管代谢医学专业委员会组织国内相关专家,起草发布了《他汀不耐受的临床诊断与处理中国专家共识》,旨在提高他汀不耐受的基本认知和ASCVD的防治水平。本文就此共识的核心要点作一解读,以飨读者。

It is well-known that elevated low-density lipoprotein cholesterol(LDL-C) is a causal risk factor for atherosclerotic cardiovascular disease(ASCVD), Statins are cornerstone drugs for the cause-based treatment of ASCVD, which has created a new era for ASCVD therapy. However, statin intolerance is not clinically uncommon, which there are several issue with confusion and misunderstandings. Hence, a file named Chinese Expert Consensus on the Diagnosis and Management Strategy of Patients With Statin Intolerance, like a navigator, has recently been published written by a team of experts from the Cardiovascular Metabolic Medicine Professional Committee, Expert Committee of the National Center for Cardiovascular Diseases aiming to enhance the standardized clinical application of statins and improve the prevention and clinical outcome. In this article, author briefly summarized the key points of above consensus in order to helping to comprehending the content of the consensus suggestions.